Compare Amgen, Inc. (AMGN) vs GameStop Corp. (GME) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs GameStop Corp. — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while GameStop Corp. trades at $21.68 (market cap $9.73B). The key difference: Amgen, Inc. is far larger — about 20.2× GameStop Corp.'s market cap, and Amgen, Inc. pays a 2.77% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals.
| AMGN | GME | |
|---|---|---|
Market Cap | $196.12B | $9.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $27.69 |
52-Week Low | $271.18 | $19.94 |
Enterprise Value | $241.41B | $5.70B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
GME trades at $21.68, down 1.23% today, with bearish technical signals from moving averages and a neutral RSI. Recent earnings beats in Q3 2025 through Q1 2026 show improving profitability, with net income margin at 20.45% for 2025. The company's strategic pivot includes pursuing an eBay acquisition and focusing on collectibles growth, supported by a strong balance sheet with $4.77B in cash and low debt-to-asset ratio of 0.28.
Outlook is mixed: strong fundamentals and strategic initiatives offer upside, but technical weakness and competitive risks in physical media decline pose challenges. Analyst consensus is cautious with only 16.67% buy ratings, reflecting skepticism over execution of ambitious plans like the eBay bid amid shifting industry dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →
